Targeting Protein Kinase C in Glioblastoma Treatment
Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor and is associated with a poor prognosis. Despite the use of combined treatment approaches, recurrence is almost inevitable and survival longer than 14 or 15 months after diagnosis is low. It is therefore necessary to identify...
Main Authors: | Noelia Geribaldi-Doldán, Irati Hervás-Corpión, Ricardo Gómez-Oliva, Samuel Domínguez-García, Félix A. Ruiz, Irene Iglesias-Lozano, Livia Carrascal, Ricardo Pardillo-Díaz, José L. Gil-Salú, Pedro Nunez-Abades, Luis M. Valor, Carmen Castro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/4/381 |
Similar Items
-
Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments
by: Ricardo Gómez-Oliva, et al.
Published: (2021-01-01) -
Research progress of drug resistance mechanisms to temozolomide in glioblastoma: A narrative review
by: Allen Lu
Published: (2022-01-01) -
Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies
by: Hyunkoo Kang, et al.
Published: (2022-06-01) -
Editorial: Neural Stem Cells of the Subventricular Zone: From Neurogenesis to Glioblastoma Origin
by: Esperanza R. Matarredona, et al.
Published: (2021-09-01) -
Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis
by: Bianca Maria Scicchitano, et al.
Published: (2018-09-01)